Invivyd Inc (IVVD) Stock Price, Quote & News

Company Profile

Invivyd, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's pipeline includes PEMGARDA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate, which is in preclinical studies for the prevention or treatment of COVID-19; and Adintrevimab that is in pha...

Industry: Biotechnology

Sector: Healthcare

Phone: 781 819 0080

Website: invivyd.com

Address:

1601 Trapelo Road, Suite 178, Waltham, United States

Cosmos99 Aug. 8 at 9:55 AM

$IVVD WSJ 8th August "The Race to Find a Measles Treatment as Infections Surge" "Scientists across the country including at biotechs Invivyd and Saravir Biopharma—and institutions such as Vanderbilt University Medical Center and Georgia State University—are in the early stages of measles-treatment development. The drugs are still a ways from becoming available to patients but could offer alternatives to people who are immunocompromised, don’t respond to the measles vaccine or are vaccine skeptics."

1 · Reply

trader2sde Aug. 8 at 3:46 AM

$IVVD Where the summer COVID-19 infections are hitting hardest: Bad news for Alabama waste waters infested.... in several States While for most of the country, wastewater viral activity level for coronavirus is currently low, Alabama is one of seven states where it is high. Others are Kentucky, Florida, Louisiana, California, Texas and Alaska, with the last two very high. Updated: Aug. 05, 2025, 12:01 p.m.|Published: Aug. 05, 2025, 6:00 a.m. https://www.al.com/news/2025/08/alabama-one-of-the-only-places-in-the-country-where-rates-are-high-in-sewage.html

0 · Reply

trader2sde Aug. 8 at 2:31 AM

$IVVD volume today and up. next week...

0 · Reply

alexx013 Aug. 7 at 10:32 AM

$IVVD is ripe

0 · Reply

Bbbooo Aug. 7 at 8:07 AM

$IVVD Thing is that despite all these “positive news” there has been no movement whatsoever… I hope this strategy of being silent not yet announcing earnings or FDA meetings works…

0 · Reply

trader2sde Aug. 6 at 7:51 PM

$IVVD AUGUST 4, 2025 NCCN Guidelines Recommend mAbs for COVID-19 PrEP in People With Cancer https://www.idse.net/Covid-19/Article/08-25/NCCN-Guidelines-Recommend-mAbs-for-COVID-19-PrEP-in-People-With-Cancer/77807 By IDSE News Staff The National Comprehensive Cancer Network (NCCN) practice guidelines recommended the use of available monoclonal antibodies (mAbs) for pre-exposure prophylaxis of COVID-19.

0 · Reply

TheFnFortune Aug. 6 at 1:58 PM

$IVVD The door is wide open for ivvd https://time.com/7307775/mrna-vaccines-rfk-jr-hhs/

0 · Reply

Cosmos99 Aug. 6 at 11:06 AM

$IVVD AZ not pursuing FDA approval for sipavibart may potentially; 1) open EU and Japan market for Pemgarda, through licensing/ partnerships 2) Invivyd a target for acquisition/ partnership particularly with continued Pemgarda efficacy and waning demand for vaccine ( eying vyd2311) Any thoughts?

1 · Reply

trader2sde Aug. 6 at 2:32 AM

$IVVD Nevertheless, Kennedy said, "HHS has determined that mRNA technology poses more risk than benefits for these respiratory viruses." He argued mRNA-based vaccines can stop working properly if the virus that they target mutates too much, citing coronavirus as an example. "A single mutation can make mRNA vaccines ineffective," Kennedy said.

0 · Reply

trader2sde Aug. 6 at 2:31 AM

$IVVD RFK FDA in full war against mrna vaccines: RFK Jr. halts $500 million for mRNA vaccine research Updated on: August 5, 2025 / 9:36 PM EDT / CBS News https://www.cbsnews.com/news/rfk-jr-halts-500-million-for-mrna-vaccine-research/?utm_source=firefox-newtab-en-us

0 · Reply

Scientist Dr. Akiko Iwasaki Joins SPEAR Study Group to Investigate Monoclonal Antibodies for Long COVID and COVID-19 Post-Vaccination Syndrome

Jul 21, 2025, 7:05 AM EDT - 17 days ago

National Comprehensive Cancer Network® (NCCN®) Guidelines Recommend Monoclonal Antibodies for COVID-19 Prevention in People with Cancer; New Data Published in JAMA Oncology Underscore Severe Impact of COVID-19 on This Population

Jul 2, 2025, 7:01 AM EDT - 5 weeks ago

Invivyd and Leading Researchers Form SPEAR (Spike Protein Elimination and Recovery) Study Group to Assess the Effects of Monoclonal Antibody Therapy for Long COVID and COVID-19 Post-Vaccination Syndrome

Jun 26, 2025, 7:01 AM EDT - 6 weeks ago

Invivyd Announces Positive Full Phase 1/2 Clinical Data for VYD2311, a Next Generation COVID-19 Monoclonal Antibody for Potential Use as a Non-Vaccine Preventative and for Treatment of Active Infection

May 27, 2025, 7:01 AM EDT - 2 months ago

Invivyd Announces Publication of Landmark CANOPY Phase 3 PEMGARDA® (pemivibart) Clinical Trial; Results Underscore Strong Efficacy of Monoclonal Antibodies in Preventing COVID-19 in a Modern U.S. Population Against Relevant, Immune-Evasive SARS-CoV-2 Virus

May 23, 2025, 7:01 AM EDT - 2 months ago

Invivyd Announces Inclusion of PEMGARDA® (pemivibart) in National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for B-Cell Lymphomas

May 21, 2025, 9:30 AM EDT - 2 months ago

Invivyd Commends FDA Focus on Contemporary Evidence In Evaluating Medical Interventions To Prevent COVID-19

May 15, 2025, 11:08 AM EDT - 3 months ago

Invivyd, Inc. (IVVD) Q1 2025 Earnings Call Transcript

May 15, 2025, 7:01 AM EDT - 3 months ago

Invivyd Reports First Quarter 2025 Financial Results and Recent Business Highlights

May 14, 2025, 7:01 AM EDT - 3 months ago

Invivyd Files Citizen Petition Urging FDA to Focus on Monoclonal Antibodies For Endemic-Virus-Era COVID-19 Prevention, and to Re-Assess COVID-19 Vaccine Efficacy

May 13, 2025, 7:01 AM EDT - 3 months ago

Invivyd to Participate at the H.C. Wainwright 3rd Annual BioConnect Investor Conference

May 12, 2025, 7:01 AM EDT - 3 months ago

Invivyd Announces New Pipeline Discovery Program Focused on Monoclonal Antibody Treatment for Measles

May 8, 2025, 7:01 AM EDT - 3 months ago

Invivyd to Host First Quarter 2025 Financial Results and Corporate Update Conference Call on May 15, 2025

Apr 21, 2025, 7:01 AM EDT - 3 months ago

Invivyd Announces $30M Non-dilutive Loan Facility with Silicon Valley Bank

Mar 26, 2025, 4:15 PM EDT - 4 months ago

Invivyd Appoints Ajay Royan, Founder of Mithril Capital, to its Board of Directors

Mar 20, 2025, 8:01 AM EDT - 5 months ago

Invivyd Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Recent Business Highlights

Mar 5, 2025, 7:05 AM EST - 5 months ago

Invivyd Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Currently Dominant SARS-CoV-2 Variant LP.8.1

Feb 24, 2025, 9:20 AM EST - 5 months ago

FDA Rejects Invivyd's Request To Expand Emergency Authorization For Preventive COVID-19 Antibody For Immunocompromised Patients

Feb 24, 2025, 7:05 AM EST - 5 months ago

FDA Declined Invivyd's Request to Expand Existing Emergency Use Authorization of PEMGARDA™ (pemivibart) to Include Treatment of Mild-to-Moderate COVID-19 For Immunocompromised Persons Who Have No Alternative Therapeutic Options; No Change to the Existing PEMGARDA EUA for Pre-Exposure Prophylaxis of COVID-19 in Certain Immunocompromised Patients

Feb 10, 2025, 7:00 AM EST - 6 months ago

Invivyd to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 12, 2025

Feb 5, 2025, 9:30 AM EST - 6 months ago

Invivyd Announces Partnership with Pro Football Coach Jim Harbaugh to Elevate Awareness and Ongoing Impact of COVID-19: Common, Not A Cold

Feb 4, 2025, 3:55 PM EST - 6 months ago

I See The Bull Case For Invivyd, But I'm Not Married To It

Feb 3, 2025, 6:55 AM EST - 6 months ago

Invivyd Announces Preliminary Fourth Quarter 2024 Financial Results, Strong Revenue Growth, and Reiterates Goal of Near-Term Profitability

Jan 27, 2025, 7:01 AM EST - 6 months ago

Invivyd Provides Another Positive SARS-CoV-2 Variant Data Analysis to Satisfy U.S. FDA's Gating Request for Completing Its Review of EUA Request for PEMGARDA™ (pemivibart) for the Treatment of Mild-to-Moderate COVID-19 in Certain Immunocompromised Patients

Jan 10, 2025, 7:01 AM EST - 7 months ago

Invivyd Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Dominant SARS-CoV-2 Variant XEC

Nov 14, 2024, 2:15 PM EST - 9 months ago

Invivyd, Inc. (IVVD) Q3 2024 Earnings Call Transcript

Nov 14, 2024, 7:05 AM EST - 9 months ago

Invivyd Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Nov 14, 2024, 7:01 AM EST - 9 months ago

Invivyd Announces New England Journal of Medicine Publishes Letter to the Editor Highlighting Immunobridging Pathway Leading to PEMGARDA™ (pemivibart) Emergency Use Authorization; Comments on Adjacent Third-Party Letter to the Editor

Nov 12, 2024, 8:30 AM EST - 9 months ago

Invivyd Announces Preprints Conveying CANOPY Phase 3 Clinical Trial Data Including Long-Term Protection Versus Recent JN.1 Sublineages at Low Residual Titers, and Describing a Novel Approach for Predicting Monoclonal Antibody Activity Were Uploaded to MedRxiv and BioRxiv, Respectively

Nov 6, 2024, 8:01 AM EST - 9 months ago

Invivyd to Participate in the Guggenheim Securities Healthcare Innovation Conference

Nov 6, 2024, 7:01 AM EST - 9 months ago

Invivyd to Host Third Quarter 2024 Financial Results and Corporate Update Conference Call on November 14, 2024

Oct 29, 2024, 7:03 AM EDT - 10 months ago

Invivyd Reports Preliminary Third Quarter 2024 Results, Withdraws Prior Financial Guidance, and Targets Near-Term Profitability

Oct 29, 2024, 7:01 AM EDT - 10 months ago

Invivyd Phase 3 Long-Term Exploratory Clinical Efficacy Data Shows PEMGARDA™ (pemivibart) Provided Substantial Protection from Symptomatic COVID-19 Versus Placebo Over Six Months of Follow-Up, With No Additional Doses, In Immunocompetent Participants

Oct 16, 2024, 7:01 AM EDT - 10 months ago

Invivyd to Present PEMGARDA™ (pemivibart) Data at Infectious Disease Week (IDWeek) 2024

Oct 1, 2024, 7:01 AM EDT - 11 months ago

Invivyd Announces U.S. FDA Has Updated the PEMGARDA™ EUA Fact Sheet with Accurate SARS-CoV-2 Variant Susceptibility and PEMGARDA Activity Data

Sep 23, 2024, 7:01 AM EDT - 11 months ago

Invivyd Provides Detailed Virology Data and Analysis of SARS-CoV-2 Structural Biology Predicting Anticipated Neutralization Activity for PEMGARDA™ (pemivibart)

Sep 12, 2024, 7:01 AM EDT - 11 months ago

Invivyd at the Ready for Upcoming Respiratory Virus Season with PEMGARDA™ (pemivibart) to Help Protect Vulnerable Immunocompromised Persons from COVID-19

Sep 5, 2024, 7:01 AM EDT - 1 year ago

Invivyd to Participate in Upcoming Investor Conferences

Sep 4, 2024, 7:01 AM EDT - 1 year ago

Invivyd Doses First Participants in Phase 1 Clinical Trial of VYD2311, a Next Generation Monoclonal Antibody Candidate for COVID-19, Building on the Success of PEMGARDA™

Sep 3, 2024, 7:01 AM EDT - 1 year ago

Invivyd Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Dominant SARS-CoV-2 Variants KP.3.1.1 and LB.1, and Other Variants of Interest

Aug 27, 2024, 7:01 AM EDT - 1 year ago

Invivyd Announces PEMGARDA™ (pemivibart) Demonstrated 84% Relative Risk Reduction in Symptomatic COVID-19 Compared to Placebo in an Exploratory Analysis from Ongoing CANOPY Phase 3 Clinical Trial

Aug 14, 2024, 2:39 PM EDT - 1 year ago

Invivyd, Inc. (IVVD) Q2 2024 Earnings Call Transcript

Aug 14, 2024, 8:01 AM EDT - 1 year ago

Invivyd Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Aug 12, 2024, 4:01 PM EDT - 1 year ago

Invivyd to Host Conference Call Discussing Second Quarter 2024 Financial Results and Business Highlights

Jul 1, 2024, 7:01 AM EDT - 1 year ago

Invivyd Announces its Addition to the Russell 2000® and Russell 3000® Indexes

Jun 14, 2024, 7:01 AM EDT - 1 year ago

Invivyd Announces Antiviral Activity of VYD222 (pemivibart) Against SARS-CoV-2 KP.1.1 FLiRT & KP.3 Variants

Jun 3, 2024, 4:01 PM EDT - 1 year ago

Invivyd to Participate at the Jefferies Global Healthcare Conference

May 31, 2024, 7:05 AM EDT - 1 year ago

Invivyd Announces General Alignment with U.S. FDA on a Repeatable, Expedient Emergency Use Authorization Pathway for the Prevention and Treatment of Symptomatic COVID-19, Based on Compact Clinical Programs to Establish Safety and Immunobridging for Serial

May 31, 2024, 7:00 AM EDT - 1 year ago

Invivyd Announces the Appointment of Timothy Lee as Chief Commercial Officer

May 29, 2024, 7:00 AM EDT - 1 year ago

Invivyd to Present Data at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting and 2024 American Transplant Congress (ATC)

Cosmos99 Aug. 8 at 9:55 AM

1 · Reply

trader2sde Aug. 8 at 3:46 AM

0 · Reply

trader2sde Aug. 8 at 2:31 AM

$IVVD volume today and up. next week...

0 · Reply

alexx013 Aug. 7 at 10:32 AM

$IVVD is ripe

0 · Reply

Bbbooo Aug. 7 at 8:07 AM

$IVVD Thing is that despite all these “positive news” there has been no movement whatsoever… I hope this strategy of being silent not yet announcing earnings or FDA meetings works…

0 · Reply

trader2sde Aug. 6 at 7:51 PM

0 · Reply

TheFnFortune Aug. 6 at 1:58 PM

$IVVD The door is wide open for ivvd https://time.com/7307775/mrna-vaccines-rfk-jr-hhs/

0 · Reply

Cosmos99 Aug. 6 at 11:06 AM

1 · Reply

trader2sde Aug. 6 at 2:32 AM

0 · Reply

trader2sde Aug. 6 at 2:31 AM

0 · Reply

trader2sde Aug. 6 at 1:57 AM

$IVVD

0 · Reply

Cosmos99 Aug. 5 at 5:50 PM

$IVVD Pemgarda competitor drops out AstraZeneca quietly discontinues COVID-19 preventive in the US The company will not pursue FDA approval for sipavibart AstraZeneca has elected not to move forward with a COVID-19 preventive in the US, despite approvals in other parts of the world, after resistance emerged in a late-stage clinical trial. AstraZeneca spokesperson Fiona Cookson told C&EN Friday that the company is “not currently pursuing a [Biologics License Application] in the US for COVID-19 prophylaxis” for sipavibart, a monoclonal antibody designed to prevent symptomatic COVID-19 in people whose immune systems are compromised. No competitor to Pemgarda in the US!

2 · Reply

Nik_CA Aug. 5 at 3:00 PM

$IVVD Some news might be shared soon. Just my opinion.

1 · Reply

trader2sde Aug. 5 at 1:43 PM

$IVVD New measles cases reported in Wisconsin, Wyoming, New Jersey https://www.cidrap.umn.edu/covid-19/kff-poll-shows-most-americans-plan-skip-fall-covid-booster

0 · Reply

trader2sde Aug. 5 at 1:41 PM

$IVVD https://www.cidrap.umn.edu/covid-19/kff-poll-shows-most-americans-plan-skip-fall-covid-booster KFF poll shows most Americans plan to skip fall COVID booster

0 · Reply

Wanggamza Aug. 5 at 5:28 AM

$IVVD where is the neeeewwwws Give us just awesome voice juice

0 · Reply

trader2sde Aug. 5 at 12:19 AM

$IVVD It has been estimated that 400 million people, globally, may have long COVID, and nearly half of them meet criteria for ME/CFS.https://medicalxpress.com/news/2025-08-scientists-biological-roots-covid-chronic.html#google_vignette

0 · Reply

trader2sde Aug. 4 at 11:06 PM

$IVVD https://nypost.com/2025/08/04/us-news/flesh-eating-bacteria-cases-rising-across-the-gulf-coast-leaving-1-in-5-dead/ ‘Flesh-eating bacteria’ cases rising across the Gulf Coast — killing 1 in 5 who contract the nasty infection Vibrio vulnificus, a nasty bacterial infection that can cause blood poisoning, and four deaths. staggering nr ie 20% death rate once infected. tb,measles, flesh eating bacteria etc etc. global warming and crazy invasive immigration ?. anyway, positive environment for companies likes IVVD.

0 · Reply

trader2sde Aug. 4 at 5:30 AM

$IVVD RFK goes after hospitals now and their rewarding for reporting covid vaccination rates... https://www.zerohedge.com/political/rfk-jr-announces-repeal-policy-rewarded-hospitals-reporting-staff-vaccination-rates RFK Jr. Announces Repeal Of Policy That Rewarded Hospitals For Reporting Staff Vaccination Rates

0 · Reply

trader2sde Aug. 3 at 1:00 PM

$IVVD CDC Flags 40-State COVID Growth While Omicron Offshoot Variant NB 1.8.1 Drives Summer Spike Fueled by a fast-growing new variant, COVID-19 infections are regaining ground just as summer travel peaks.https://dailyvoice.com/nj/bradley-beach-avon-belmar/covid-19-infections-on-rise-nationwide-as-summer-travel-peaks-new-variant-spreads/

0 · Reply

trader2sde Aug. 3 at 6:52 AM

$IVVD COVID rising in California. How bad will this summer be? https://www.latimes.com/california/story/2025-07-28/covid-rising-in-california-how-bad-will-this-summer-be (note: we all know here leftist propaganda press loves to push for vaccines and covid alarming.... nevertheless..)

0 · Reply

trader2sde Aug. 3 at 2:02 AM

$IVVD reminder Invivyd is developings mabs against mealses https://www.zerohedge.com/medical/number-measles-cases-canada-almost-triple-us Number of Measles Cases In Canada Almost Triple That Of US here US nr https://www.businessinsider.com/charts-show-measles-spreading-in-us-states-2025-4

0 · Reply

Market Cap	86.01M
Revenue (ttm)	25.38M
Net Income (ttm)	-169.93M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-669.54%
Debt to Equity Ratio	0.00

Volume	1,562,200
Avg Vol	1,112,718
Day's Range	N/A - N/A
Shares Out	119.96M
Stochastic %K	46%
Beta	0.51
Analysts	Strong Sell
Price Target	$5.95